DA024355/DA/NIDA NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2007	1
2008	3
2009	5
2010	4
2011	7
2012	5
2013	8
2014	4
2015	5
2016	5
2017	2
2018	1
2022	1
2023	2
2024	0

1

One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial.

Kliewer KL, Gonsalves N, Dellon ES, Katzka DA, Abonia JP, Aceves SS, Arva NC, Besse JA, Bonis PA, Caldwell JM, Capocelli KE, Chehade M, Cianferoni A, Collins MH, Falk GW, Gupta SK, Hirano I, Krischer JP, Leung J, Martin LJ, Menard-Katcher P, Mukkada VA, Peterson KA, Shoda T, Rudman Spergel AK, Spergel JM, Yang GY, Zhang X, Furuta GT, Rothenberg ME. Kliewer KL, et al. Lancet Gastroenterol Hepatol. 2023 May;8(5):408-421. doi: 10.1016/S2468-1253(23)00012-2. Epub 2023 Feb 28. Lancet Gastroenterol Hepatol. 2023. PMID: 36863390 Free PMC article. Clinical Trial.

2

Neuropeptide systems and schizophrenia.

LaCrosse AL, Olive MF. LaCrosse AL, et al. CNS Neurol Disord Drug Targets. 2013 Aug;12(5):619-32. doi: 10.2174/1871527311312050010. CNS Neurol Disord Drug Targets. 2013. PMID: 23574175 Review.

3

Neurokinin-1 (NK₁) receptor antagonists as possible therapeutics for psychostimulant use disorders.

Olive MF. Olive MF. CNS Neurol Disord Drug Targets. 2015;14(6):700-6. doi: 10.2174/1871527314666150529145811. CNS Neurol Disord Drug Targets. 2015. PMID: 26022261 Review.

4

Abuse liability of novel 'legal high' designer stimulants: evidence from animal models.

Watterson LR, Watterson E, Olive MF. Watterson LR, et al. Behav Pharmacol. 2013 Sep;24(5-6):341-55. doi: 10.1097/FBP.0b013e3283641ec8. Behav Pharmacol. 2013. PMID: 23839028 Free PMC article. Review.

5

Structural and functional plasticity of dendritic spines - root or result of behavior?

Gipson CD, Olive MF. Gipson CD, et al. Genes Brain Behav. 2017 Jan;16(1):101-117. doi: 10.1111/gbb.12324. Epub 2016 Oct 2. Genes Brain Behav. 2017. PMID: 27561549 Free PMC article. Review.

6

The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans.

Taylor SB, Lewis CR, Olive MF. Taylor SB, et al. Subst Abuse Rehabil. 2013 Feb 8;4:29-43. doi: 10.2147/SAR.S39684. eCollection 2013. Subst Abuse Rehabil. 2013. PMID: 24648786 Free PMC article. Review.

7

Metabotropic glutamate receptor ligands as potential therapeutics for addiction.

Olive MF. Olive MF. Curr Drug Abuse Rev. 2009 Jan;2(1):83-98. doi: 10.2174/1874473710902010083. Curr Drug Abuse Rev. 2009. PMID: 19630739 Free PMC article. Review.

8

Early-life stress interactions with the epigenome: potential mechanisms driving vulnerability toward psychiatric illness.

Lewis CR, Olive MF. Lewis CR, et al. Behav Pharmacol. 2014 Sep;25(5-6):341-51. doi: 10.1097/FBP.0000000000000057. Behav Pharmacol. 2014. PMID: 25003947 Free PMC article. Review.

9

Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders.

Cleva RM, Olive MF. Cleva RM, et al. Molecules. 2011 Mar 2;16(3):2097-106. doi: 10.3390/molecules16032097. Molecules. 2011. PMID: 21368721 Free PMC article. Review.

10

Glutamatergic medications for the treatment of drug and behavioral addictions.

Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Olive MF, et al. Pharmacol Biochem Behav. 2012 Feb;100(4):801-10. doi: 10.1016/j.pbb.2011.04.015. Epub 2011 Apr 22. Pharmacol Biochem Behav. 2012. PMID: 21536062 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

42 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year